- $99.29m
- -$120.71m
- $19.09m
Lenz climbs on quarterly revenue beat
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Lenz Therapeutics, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary
LENZ Therapeutics Q2 revenue rises on VIZZ sales
Lenz Therapeutics, Inc. Expected To Post A Loss Of $1.07 A Share: Earnings Preview
Lenz Therapeutics Inc Expected To Post A Loss Of $1.07 A Share: Earnings Preview
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
LENZ Therapeutics Q1 revenue rises on VIZZ launch
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
LENZ Therapeutics Q4 net loss widens on VIZZ launch costs
Brief: Lenz Therapeutics Launch Of “Make It Vizzable” With Sarah Jessica Parker As A Brand Ambassador
Brief: Lenz Therapeutics And Lunatus Announce Partnership For Vizz™
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
LENZ Therapeutics Q3 net loss widens on increased SG&A expenses
Lenz Therapeutics rises after securing FDA nod for its eye-disorder treatment
Brief: LENZ Therapeutics Reports Second Quarter 2025 Financial Results And Recent Corporate Highlights